Ionis Pharmaceuticals Ownership
| IONS Stock | USD 32.91 0.18 0.55% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 149 M | Current Value 150 M | Avarage Shares Outstanding 123.8 M | Quarterly Volatility 17.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Ionis |
Ionis Stock Ownership Analysis
About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 101.16. Ionis Pharmaceuticals recorded a loss per share of 3.04. The entity had not issued any dividends in recent years. Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California. Ionis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 660 people. To learn more about Ionis Pharmaceuticals call Stanley Crooke at 760 931 9200 or check out https://www.ionis.com.Besides selling stocks to institutional investors, Ionis Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Ionis Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Ionis Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Ionis Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Ionis Pharmaceuticals Insider Trades History
Less than 1% of Ionis Pharmaceuticals are currently held by insiders. Unlike Ionis Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Ionis Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Ionis Pharmaceuticals' insider trades
Ionis Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ionis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ionis Pharmaceuticals backward and forwards among themselves. Ionis Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Ionis Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 2.7 M | Citadel Advisors Llc | 2024-12-31 | 2.2 M | Deep Track Capital, Lp | 2024-12-31 | 1.9 M | Ubs Group Ag | 2024-12-31 | 1.9 M | Macquarie Group Ltd | 2024-12-31 | 1.8 M | Norges Bank | 2024-12-31 | 1.7 M | Clearbridge Advisors, Llc | 2024-12-31 | 1.6 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.5 M | Two Sigma Advisers, Llc | 2024-12-31 | 1.3 M | Fmr Inc | 2024-12-31 | 22.7 M | Vanguard Group Inc | 2024-12-31 | 16.5 M |
Ionis Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ionis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ionis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ionis Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ionis Pharmaceuticals Outstanding Bonds
Ionis Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ionis Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ionis bonds can be classified according to their maturity, which is the date when Ionis Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Ionis Pharmaceuticals Corporate Filings
F4 | 13th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 12th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 13th of February 2025 Other Reports | ViewVerify | |
| 7th of February 2025 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.